R M Pedapenki

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Patients with hematological malignancies that are highly proliferative and have high tumor burden are at high risk of developing hyperuricemia and tumor lysis syndrome (TLS), spontaneously and while undergoing chemotherapy. AIM To assess the safety and efficacy of a new generic formulation of recombinant rasburicase in prevention and treatment(More)
  • 1